Abstract: The present invention provides a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1' are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2' are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3' are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion.The invention also provides a method of treating a subject having a condition associated with the presence of free radicals in quantities sufficient to cause undesirable symptoms.

Abstract: The present invention provides a pharmaceutical composition of a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1, are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2, are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3, are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion.

Abstract: The present invention provides pharmaceutical compositions for the treatment of tumor cells in a subject of for the treating of undesirable symptoms associated with the presence of free radicals. The compositions comprising a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1, are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2, are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3, are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion and a pharmaceutically acceptable carrier.

Abstract: The present invention provides a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1, are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2, are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3, are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion.The invention also provides a method of treating a subject having a condition associated with the presence of free radicals in quantities sufficient to cause undesirable symptoms.

Abstract: The present invention provides a complex compound having the structure: ##STR1## wherein R.sub.1 and R.sub.1, are the same or different and each is an alkyl group, a phenyl group or a substituted derivative of a phenyl group;wherein R.sub.2 and R.sub.2, are the same or different and each is hydrogen, an unbranched alkyl group, a halide or a group having the structure ##STR2## wherein R is hydrogen, an alkoxide group, an alkyl group, or OH; wherein R.sub.3 and R.sub.3, are the same or different and each is hydrogen or an alkyl group;wherein X and X' are the same or different and each is a water soluble group having weak to intermediate ligand field strength; andQ is a soluble, pharmaceutically acceptable negative ion.The invention also provides a method of treating a subject having a condition associated with the presence of free radicals in quantities sufficient to cause undesirable symptoms.

Abstract: A container for holding and culturing a lens is disclosed, comprising a transparent base member, a transparent lens carrier supported laterally in the base member and having a central aperture, and a transparent cover engaging the base member for enclosing the lens carrier within the container. The base is circular in top view, and in sectional elevation is in the form of a flanged U-shape, forming a well. The lens carrier is a circular plate with a central aperture. The lip of the aperture tapers downwardly in order to support the outer rim of the lens to be tested. The cover has an annular flange and a raised center section with angled sidewalls. The sidewalls have two flat sections offset from each other by 90 degrees, which act as viewing ports. The lens to be studied is centered in the aperture in the bottom of the lens carrier. The lens carrier is ordinarily provided with passage holes to permit the free passage of the culture medium from one side of the lens to the other.

Abstract: A new method of treating a burn is disclosed wherein a cobalt-containing metallo-organic complex is applied to the burn site to promote epithelialization and in some cases hair follicle preservation as well.

Abstract: A method of treating an inflammatory condition in a mammalian subject, particularly arthritis, comprising the steps of administering an effective and nontoxic dose for an inflammation ameliorating period to the subject of at least one metallo-organic complex capable of in vivo superoxide anti-oxidant effects and wherein the metal of the complex is selected from the group which consists of cobalt and iron.

Abstract: A method for in vitro evaluation of focal length changes in a lens is disclosed, involving the steps of projecting parallel laser beams through the lens at at least two points, examining the convergence of the beams after exiting the lens to determine the focal length of the lens, and after a period of time, repeating these steps and comparing the focal length. Preferably, a scanning laser is used so that a number of beams pass through different spots on the lens, so that the spherical aberration of the lens may also be determined and compared over time. Apparatus is disclosed for carrying out the method, comprising a carousel plate having a number of spaced holes for receiving lens containers. A carousel drive servo motor rotates the carousel from lens container position to lens container position. A helium-neon laser is mounted horizontally on an X-Y table, and the laser beam is deflected upwardly through a lens held in a lens container.